BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 26, 2020--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March:
Event: The 40th Annual Cowen Health Care Conference
Date: Tuesday, March 3, 2020
Presentation Time: 9:20 a.m. ET
Location: Boston, MA
Event: The 32nd Annual ROTH Conference
Date: Monday, March 16, 2020
Presentation Time: 2:00 p.m. PT
Location: Laguna Niguel, CA
A live webcast of each presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com. Replays will be available following each webcast.
Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. For more information, please visit www.aimmune.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005149/en/
Source: Aimmune Therapeutics, Inc.